Do analysts rate ENVB or CLRB?

Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 341.77%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, ENVB or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is ENVB or CLRB more profitable?

Enveric Biosciences' return on equity of -220.97% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% Cellectar Biosciences N/A -349.24% -153.18%

Does the media favor ENVB or CLRB?

In the previous week, Cellectar Biosciences had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Enveric Biosciences. Cellectar Biosciences' average media sentiment score of 0.37 beat Enveric Biosciences' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MDCX or ENVB?

Medicus Pharma currently has a consensus price target of $9.00, indicating a potential upside of 2,016.15%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Medicus Pharma is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MDCX or ENVB?

Medicus Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A

Is MDCX or ENVB more profitable?

Enveric Biosciences' return on equity of -220.97% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Enveric Biosciences N/A -220.97% -177.47%

Does the media prefer MDCX or ENVB?

In the previous week, Medicus Pharma had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for Medicus Pharma and 1 mentions for Enveric Biosciences. Medicus Pharma's average media sentiment score of 1.05 beat Enveric Biosciences' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MYNZ or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MYNZ or ENVB more profitable?

Mainz Biomed's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Enveric Biosciences N/A -220.97% -177.47%

Do analysts rate ENVB or HOWL?

Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 901.07%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has stronger valuation and earnings, ENVB or HOWL?

Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A Werewolf Therapeutics N/A N/A -$60.82M -$1.24 N/A

Is ENVB or HOWL more profitable?

Werewolf Therapeutics' return on equity of -208.23% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% Werewolf Therapeutics N/A -208.23% -75.12%

Does the media favor ENVB or HOWL?

In the previous week, Werewolf Therapeutics had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 1 mentions for Enveric Biosciences. Werewolf Therapeutics' average media sentiment score of 0.47 beat Enveric Biosciences' score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Werewolf Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SNSE or ENVB?

Sensei Biotherapeutics presently has a consensus target price of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Sensei Biotherapeutics is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SNSE or ENVB?

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A

Is SNSE or ENVB more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Enveric Biosciences N/A -220.97% -177.47%

Does the media refer more to SNSE or ENVB?

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 1 articles in the media. Sensei Biotherapeutics' average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Enveric Biosciences (ENVB) Competitors

$1.31 -0.04 (-2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 -0.02 (-1.15%)

As of 06:17 PM Eastern

Compare

ENVB vs. CLRB, MDCX, MYNZ, HOWL, and SNSE

Should you buy Enveric Biosciences stock or one of its competitors? MarketBeat compares Enveric Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enveric Biosciences include Cellectar Biosciences (CLRB), Medicus Pharma (MDCX), Mainz Biomed (MYNZ), Werewolf Therapeutics (HOWL), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry.

How does Enveric Biosciences compare to Cellectar Biosciences?

Enveric Biosciences (NASDAQ:ENVB) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Enveric Biosciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Enveric Biosciences. Cellectar Biosciences' average media sentiment score of 0.37 beat Enveric Biosciences' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 341.77%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Enveric Biosciences' return on equity of -220.97% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Cellectar Biosciences beats Enveric Biosciences on 9 of the 13 factors compared between the two stocks.

How does Enveric Biosciences compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Enveric Biosciences' return on equity of -220.97% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Enveric Biosciences	N/A	-220.97%	-177.47%

Medicus Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

13.8% of Enveric Biosciences shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Medicus Pharma had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for Medicus Pharma and 1 mentions for Enveric Biosciences. Medicus Pharma's average media sentiment score of 1.05 beat Enveric Biosciences' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma currently has a consensus price target of $9.00, indicating a potential upside of 2,016.15%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Medicus Pharma is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Medicus Pharma has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Summary

Medicus Pharma beats Enveric Biosciences on 7 of the 13 factors compared between the two stocks.

How does Enveric Biosciences compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Enveric Biosciences has lower revenue, but higher earnings than Mainz Biomed. Enveric Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	20.46	-$21.65M	-$65.60	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Mainz Biomed's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Enveric Biosciences	N/A	-220.97%	-177.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enveric Biosciences had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Overall Sentiment
Mainz Biomed	Neutral
Enveric Biosciences	Neutral

13.8% of Enveric Biosciences shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Mainz Biomed beats Enveric Biosciences on 6 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Werewolf Therapeutics?

Enveric Biosciences (NASDAQ:ENVB) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Werewolf Therapeutics had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 1 mentions for Enveric Biosciences. Werewolf Therapeutics' average media sentiment score of 0.47 beat Enveric Biosciences' score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A

Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 901.07%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Werewolf Therapeutics' return on equity of -208.23% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Enveric Biosciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Summary

Werewolf Therapeutics beats Enveric Biosciences on 10 of the 13 factors compared between the two stocks.

How does Enveric Biosciences compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 1 articles in the media. Sensei Biotherapeutics' average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sensei Biotherapeutics presently has a consensus target price of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Sensei Biotherapeutics is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Sensei Biotherapeutics' return on equity of -83.59% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Enveric Biosciences	N/A	-220.97%	-177.47%

Summary

Enveric Biosciences beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.82M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-0.06	20.68	25.17	24.00
Price / Sales	N/A	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.19	8.26	10.76	6.41
Net Income	-$8.77M	$23.91M	$3.56B	$337.14M
7 Day Performance	0.77%	3.05%	1.37%	-0.48%
1 Month Performance	-40.72%	2.40%	0.81%	0.49%
1 Year Performance	-91.27%	56.35%	30.53%	28.16%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	0.7044 of 5 stars	$1.31 -3.0%	N/A	-91.0%	$4.82M	N/A	N/A	20	Gap Up
CLRB Cellectar Biosciences	4.1916 of 5 stars	$2.44 -0.6%	$11.00 +351.7%	-72.0%	$19.47M	N/A	N/A	10
MDCX Medicus Pharma	2.7258 of 5 stars	$0.34 +2.1%	$9.00 +2,531.6%	-80.3%	$19.32M	N/A	N/A	N/A	Positive News
MYNZ Mainz Biomed	N/A	$2.12 +22.5%	N/A	+10.8%	$19.21M	$659.94K	N/A	30	Gap Up High Trading Volume
HOWL Werewolf Therapeutics	3.2637 of 5 stars	$0.40 +9.7%	$3.75 +849.4%	-71.1%	$19.20M	$1.88M	N/A	40	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. CLRB, MDCX, MYNZ, HOWL, and SNSE

How does Enveric Biosciences compare to Cellectar Biosciences?

Summary

How does Enveric Biosciences compare to Medicus Pharma?

Summary

How does Enveric Biosciences compare to Mainz Biomed?

Summary

How does Enveric Biosciences compare to Werewolf Therapeutics?

Summary

How does Enveric Biosciences compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. CLRB, MDCX, MYNZ, HOWL, and SNSE

How does Enveric Biosciences compare to Cellectar Biosciences?

Do insiders & institutionals have more ownership in ENVB or CLRB?

Which has more risk and volatility, ENVB or CLRB?

Does the media favor ENVB or CLRB?

Do analysts rate ENVB or CLRB?

Which has higher valuation and earnings, ENVB or CLRB?

Is ENVB or CLRB more profitable?

Summary

How does Enveric Biosciences compare to Medicus Pharma?

Is MDCX or ENVB more profitable?

Which has higher valuation & earnings, MDCX or ENVB?

Do insiders & institutionals believe in MDCX or ENVB?

Does the media prefer MDCX or ENVB?

Do analysts rate MDCX or ENVB?

Which has more volatility & risk, MDCX or ENVB?

Summary

How does Enveric Biosciences compare to Mainz Biomed?

Which has more risk and volatility, MYNZ or ENVB?

Which has stronger earnings & valuation, MYNZ or ENVB?

Is MYNZ or ENVB more profitable?

Do analysts recommend MYNZ or ENVB?

Does the media refer more to MYNZ or ENVB?

Do institutionals and insiders believe in MYNZ or ENVB?

Summary

How does Enveric Biosciences compare to Werewolf Therapeutics?

Does the media favor ENVB or HOWL?

Which has stronger valuation and earnings, ENVB or HOWL?

Do analysts rate ENVB or HOWL?

Is ENVB or HOWL more profitable?

Do insiders & institutionals believe in ENVB or HOWL?

Which has more risk and volatility, ENVB or HOWL?

Summary

How does Enveric Biosciences compare to Sensei Biotherapeutics?

Do insiders and institutionals hold more shares of SNSE or ENVB?

Which has more risk and volatility, SNSE or ENVB?

Does the media refer more to SNSE or ENVB?

Do analysts prefer SNSE or ENVB?

Which has higher valuation & earnings, SNSE or ENVB?

Is SNSE or ENVB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools